Faeth Therapeutics (FTH) Net Income (2020 - 2026)
Faeth Therapeutics' (FTH) quarterly Net Income came in at -$182.4 million in Q1 2026, down 2378.78% YoY from $8.0 million in Q1 2025, and down 5192.77% on a QoQ basis from -$3.4 million in Q4 2025.
Faeth Therapeutics (FTH) Net Income (2020 - 2026) Analysis & Trends
Faeth Therapeutics (FTH) has 7 years of Net Income data on file, last reported at -$182.4 million in Q1 2026.
- Quarterly Net Income fell 2378.78% year-over-year to -$182.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$200.1 million (down 446.53% YoY) and the FY2025 annual result came in at -$81.8 million, up 7.25% from the prior year.
- Net Income eased to -$182.4 million in Q1 2026, from -$3.4 million in the prior quarter.
- In the past five years, Net Income ranged from a high of -$3.4 million in Q4 2025 to a low of -$182.4 million in Q1 2026.
- A 5-year average of -$20.2 million and a median of -$11.2 million in 2022 frame the typical range for Net Income.
- Annual changes were most pronounced in 2022 — Net Income soared 57.83% — and 2026, when it tumbled 2378.78%.
- Tracing FTH's Net Income over 5 years: stood at -$12.2 million in 2022, then soared by 44.54% to -$6.8 million in 2023, then increased by 12.09% to -$6.0 million in 2024, then surged by 42.22% to -$3.4 million in 2025, then tumbled by 5192.77% to -$182.4 million in 2026.
- The last three Net Income figures came in at -$182.4 million (Q1 2026), -$3.4 million (Q4 2025), and -$6.7 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.69 Bn | 131.84 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 86.54 Bn | 78.54 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 65.27 Bn | 60.09 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 59.41 Bn | 54.27 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 42.12 Bn | 37.02 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.80 Bn | 28.49 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.07 Bn | 9.68 Bn | 668.28 Mn | -355.03 Mn |
| 8 | Insmed | 27.55 Bn | 26.39 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.28 Bn | 26.44 Bn | - | 81.49 Mn |
| 10 | Faeth Therapeutics | 184.08 Mn | 184.08 Mn | - | -16.13 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -22.61 Mn |
| Mar 31, 2026 | -182.39 Mn |
| Dec 31, 2025 | -3.45 Mn |
| Sep 30, 2025 | -6.74 Mn |
| Jun 30, 2025 | -7.54 Mn |
| Mar 31, 2025 | -7.36 Mn |
| Dec 31, 2024 | -5.96 Mn |
| Sep 30, 2024 | -11.41 Mn |
| Jun 30, 2024 | -11.88 Mn |
| Mar 31, 2024 | -9.12 Mn |
| Dec 31, 2023 | -6.78 Mn |
| Sep 30, 2023 | -9.58 Mn |
| Jun 30, 2023 | -12.13 Mn |
| Mar 31, 2023 | -11.24 Mn |
| Dec 31, 2022 | -12.23 Mn |
| Sep 30, 2022 | -20.75 Mn |
| Jun 30, 2022 | -11.20 Mn |
| Mar 31, 2022 | -13.30 Mn |
| Dec 31, 2021 | -8.85 Mn |
| Sep 30, 2021 | -24.84 Mn |